Pfizer Releases Top Line Data on Novel RA Drug

Xconomy New York — 

Pfizer (NYSE: PFEannounced that the 10 milligram dose of tofacitinib, its experimental JAK inhibitor for rheumatoid arthritis (RA), met all primary endpoints in a phase 3 study. Patients taking the drug showed statistically significant changes in the signs and symptoms of the disease, as well as a slowing of structural damage of the joints, when compared to patients on placebo. The smaller dose, 5 milligrams, improved symptoms but did not significantly reduce structural damage. The company plans to release additional data at an upcoming medical meeting.

By posting a comment, you agree to our terms and conditions.

Comments are closed.